Table 3 Effectiveness endpoints in ConcertAI data.

From: Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer

 

HR+/HER2- mBC

mTNBC

Palbociclib + fulvestrant combination therapy

Fulvestrant monotherapy

Paclitaxel-based therapy

Chemotherapy

N

292

274

381

247

Time to event outcomes; Median (95% CI)*

rwOS

32.3 (25.7, 39.7)

23.8 (20.7, 26.6)

15.6 (12.9, 17.6)

13.0 (10.6, 16.8)

rwPFS

8.6 (6.6, 10.5)

6.4 (4.9, 8.2)

5.6 (4.9, 7.1)

4.4 (3.4, 5.1)

rwTTNT

7.5 (5.9, 9.5)

4.5 (3.7, 5.0)

3.5 (3.2, 3.8)

4.2 (3.6, 5.2)

rwTTD

5.9 (4.6, 7.4)

3.0 (2.8, 3.7)

2.5 (2.3, 2.6)

2.3 (2.0, 2.8)

Tumor response; % (95% CI)a

rwRR

26.0% (21.1%, 31.5%)

13.9% (10.0%, 18.9%)

27.0% (22.6%, 31.8%)

30.0% (24.3%, 36.1%)

Missing, n (%)

82 (28.1%)

118 (43.1%)

158 (41.5%)

75 (30.4%)

  1. CI confidence interval, ORR overall response rate, rwOS real-world overall survival, rwPFS real-world progression-free survival, rwRR real-world response rate, rwTTD real-world time to discontinuation, rwTTNT real-world time to next treatment.
  2. aResponse events were captured 14+ days after the index date.
  3. *1 month = 30.4375 days.
Back to article page